AR100618A1 - Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido - Google Patents

Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Info

Publication number
AR100618A1
AR100618A1 ARP150101653A ARP150101653A AR100618A1 AR 100618 A1 AR100618 A1 AR 100618A1 AR P150101653 A ARP150101653 A AR P150101653A AR P150101653 A ARP150101653 A AR P150101653A AR 100618 A1 AR100618 A1 AR 100618A1
Authority
AR
Argentina
Prior art keywords
dissolved oxygen
human albumin
albumin
oxygen level
preparation procedure
Prior art date
Application number
ARP150101653A
Other languages
English (en)
Spanish (es)
Inventor
Costa Rierola Montserrat
Maria Ortiz Fernandez Ana
Ignacio Jorquera Nieto Juan
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of AR100618A1 publication Critical patent/AR100618A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP150101653A 2014-05-29 2015-05-27 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido AR100618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Publications (1)

Publication Number Publication Date
AR100618A1 true AR100618A1 (es) 2016-10-19

Family

ID=52003454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101653A AR100618A1 (es) 2014-05-29 2015-05-27 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Country Status (22)

Country Link
US (1) US10350274B2 (https=)
EP (1) EP2952203B9 (https=)
JP (3) JP2015224251A (https=)
KR (1) KR101960729B1 (https=)
CN (1) CN105315362B (https=)
AR (1) AR100618A1 (https=)
AU (1) AU2015202413B2 (https=)
BR (1) BR102015012091A8 (https=)
CA (1) CA2890642C (https=)
CL (1) CL2015001446A1 (https=)
ES (2) ES2524516B1 (https=)
HU (1) HUE031823T2 (https=)
IL (1) IL238898B (https=)
MX (1) MX362869B (https=)
MY (1) MY171771A (https=)
NZ (1) NZ708537A (https=)
PL (1) PL2952203T3 (https=)
PT (1) PT2952203T (https=)
RU (1) RU2657578C2 (https=)
SG (1) SG10201504137PA (https=)
TW (1) TWI607018B (https=)
ZA (1) ZA201503539B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES2900302T3 (es) 2016-04-28 2022-03-16 Alkahest Inc Fracciones de plasma como terapia para el crecimiento y la progresión del tumor
SMT202100666T1 (it) 2016-08-18 2022-01-10 Alkahest Inc Frazioni di plasma sanguigno come trattamento per disturbi cognitivi associati all'invecchiamento
WO2018200560A1 (en) 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MA53182A (fr) 2018-07-20 2021-05-26 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits à base de plasma sanguin
CN119345230A (zh) 2018-10-26 2025-01-24 万能溶剂有限公司 血浆和血浆组分用于改善疼痛的用途
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法
JP2022553837A (ja) 2019-11-04 2022-12-26 アルカヘスト,インコーポレイテッド 筋肉再生に使用するための血漿画分
AU2020388572A1 (en) 2019-11-20 2022-05-26 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
WO2024200553A1 (en) 2023-03-29 2024-10-03 Grifols Worldwide Operations Limited COMPOSITIONS AND METHODS OF PREPARATION OF BLOOD PLASMA PRODUCTS WITH REDUCED LEVELS OF FceRIß AUTOANTIBODIES
CN118166053B (zh) * 2024-03-15 2025-02-07 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
DE60234142D1 (de) * 2001-03-27 2009-12-10 Nipro Corp Albuminlösung enthaltender Kunststoffbehälter
WO2003002139A1 (fr) * 2001-06-29 2003-01-09 Asahi Kasei Kabushiki Kaisha Procede permettant d'ameliorer la stabilite de la preparation de proteines
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US7285379B2 (en) * 2003-08-28 2007-10-23 Nipro Corporation Artificial oxygen carrier and production method thereof
HRP20120994T1 (hr) * 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Also Published As

Publication number Publication date
ZA201503539B (en) 2017-01-25
TW201544510A (zh) 2015-12-01
HUE031823T2 (en) 2017-08-28
PL2952203T3 (pl) 2017-02-28
MX2015006407A (es) 2015-11-30
SG10201504137PA (en) 2015-12-30
AU2015202413A1 (en) 2015-12-17
CN105315362B (zh) 2019-10-25
EP2952203B9 (en) 2018-03-14
RU2015118453A (ru) 2016-12-10
KR101960729B1 (ko) 2019-03-21
ES2524516B1 (es) 2015-03-31
KR20160024348A (ko) 2016-03-04
JP2020111614A (ja) 2020-07-27
EP2952203B1 (en) 2016-10-26
TWI607018B (zh) 2017-12-01
CL2015001446A1 (es) 2016-05-13
MY171771A (en) 2019-10-29
ES2601137T3 (es) 2017-02-14
US20150343025A1 (en) 2015-12-03
BR102015012091A8 (pt) 2021-03-16
US20170000855A9 (en) 2017-01-05
PT2952203T (pt) 2016-11-23
NZ708537A (en) 2017-06-30
CA2890642C (en) 2019-02-12
US10350274B2 (en) 2019-07-16
BR102015012091A2 (pt) 2016-01-05
ES2524516A1 (es) 2014-12-09
JP2015224251A (ja) 2015-12-14
RU2657578C2 (ru) 2018-06-14
IL238898B (en) 2018-01-31
JP2018115210A (ja) 2018-07-26
MX362869B (es) 2019-02-20
AU2015202413B2 (en) 2017-08-31
CN105315362A (zh) 2016-02-10
CA2890642A1 (en) 2015-11-29
EP2952203A1 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
MX2015000990A (es) Analogos del glucagon.
UY36766A (es) Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
DOP2016000253A (es) Nuevos compuestos
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
CY1120125T1 (el) Διαδικασια για την παραγωγη ενος ενεσιμου διαλυματος νοραδρεναλινης σε σταθερη χαμηλη συγκεντρωση
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
DOP2016000007A (es) Pirazolpiridinas sustituidas
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
UY36150A (es) Derivados de naftiridinadiona
BR112016015190A2 (pt) Composição farmacêutica não contendo antioxidante e método de preparação da mesma
BR112017002915A2 (pt) processo para manufaturar um dispositivo de uso médico customizável e dispositivo obtido pelo dito processo
CO2019003761A2 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
CO2017003313A2 (es) Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en com-posiciones farmacéuticas
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака
UY36507A (es) Procedimiento de preparacion de albumina humana con nivel de oxigeno disuelto reducido

Legal Events

Date Code Title Description
FG Grant, registration